According to the National Therapeutic Protocol for psoriasis treatment approved in 2022, the following biological agents are available in Romania: inhibitors of tumor necrosis factor (TNF)-α including etanercept, certolizumab pegol, adalimumb, infliximab; interleukin (IL)-17, inhibitors such as ixekizumab and secukinumab; anti IL-12/23 agents such as ustekinumab; IL-23 inhibitors such as guselkumab, risankizumab and tildrakizumab. This evidence concerns the gene IL17A and psoriasis.